|Bid||82.25 x 100|
|Ask||85.95 x 100|
|Day's range||83.04 - 84.16|
|52-week range||68.48 - 84.31|
|PE ratio (TTM)||N/A|
|Expense ratio (net)||0.14%|
The tax reform bills passed by the US House and Senate reduce the corporate tax rate from 35.0% to 20.0%. According to Credit Suisse, healthcare companies pay corporate taxes as high as 30.2%.
In 3Q17, Merck (MRK) reported revenue of $10.3 billion, which reflected a ~2% fall YoY (year-over-year) and ~4% growth QoQ (quarter-over-quarter).
The Zacks Analyst Blog Highlights: U.S. Tax Reform Fund, First Trust Large Cap Growth AlphaDEX, iShares U.S. Dividend and Buyback, SPDR S&P Homebuilders
“Now, if your kid needs treatment that costs you $40,000, the government isn’t sharing that risk with you.”
Aetna (AET) is higher Friday, thanks to an upgrade from Raymond James. Analysts Michael Baker and Matt Wizman boosted their rating from Market Perform to Outperform, with a $200 price target, arguing that the stock’s risk-reward skews to the upside thanks to a potential takeover from CVS (CVS). More from the note: Approval from regulators (if announced) is probable given the vertical nature of the deal versus previously blocked horizontal (insurer-to-insurer) deals, with overlapping Medicare Part D (MAPD) being a minor fixable factor.
Pharmaceutical ETFs are publicly traded securities designed for investors who don't have the capacity to hold too many stocks but are interested in diversification.
President Donald Trump signed an executive order Thursday directing federal agencies to consider expanding health-insurance coverage in low-cost plans that are not subject to Affordable Care Act rules, ...
Shares of OrthoPediatics Corp. were trading 50% above the initial public offering price, in their public debut. The maker of medical devices for use in the pediatric orthopedic market's shares opened at ...
In the Halftime Report's quarterly stock survey, the street's top strategists share their predictions for Q42017.